

# Rebecca J Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6340543/publications.pdf>

Version: 2024-02-01

12  
papers

1,622  
citations

840776  
11  
h-index

1199594  
12  
g-index

12  
all docs

12  
docs citations

12  
times ranked

3091  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. <i>Nature Immunology</i> , 2017, 18, 1332-1341.	14.5	508
2	Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. <i>Cell</i> , 2016, 165, 1092-1105.	28.9	340
3	Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. <i>Nature</i> , 2020, 585, 277-282.	27.8	280
4	Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. <i>Cancer Research</i> , 2002, 62, 924-31.	0.9	111
5	Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity. <i>Science Immunology</i> , 2017, 2, .	11.9	83
6	Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. <i>JCI Insight</i> , 2020, 5, .	5.0	74
7	Resveratrol inhibits ovarian tumor growth in an in vivo mouse model. <i>Cancer</i> , 2016, 122, 722-729.	4.1	60
8	Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis. <i>JCI Insight</i> , 2020, 5, .	5.0	59
9	Trends and comparative effectiveness of inpatient radical hysterectomy for cervical cancer in the United States (2012–2015). <i>Gynecologic Oncology</i> , 2019, 152, 133-138.	1.4	40
10	Gynecologic melanomas: A clinicopathologic and molecular analysis. <i>Gynecologic Oncology</i> , 2017, 147, 351-357.	1.4	35
11	Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy. <i>Gynecologic Oncology</i> , 2018, 151, 1-3.	1.4	20
12	A phase II clinical trial of metformin as a cancer stem cell targeting agent in stage IIc/III/IV ovarian, fallopian tube, and primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5556-5556.	1.6	12